Today’s time-consuming diagnostics of sepsis leads to an unnecessary amount of hospital days and an overuse of broad spectrum antibiotics. Q-linea´s fully automated solutions will enable healthcare providers to accurately diagnose sepsis in the shortest possible time. Our analysis platforms will drastically reduce the time for sepsis diagnosis.
ASTar™ will deliver answers about antibiotic susceptibility within six hours directly from positive blood cultures. The ASTrID® platform will identify the cause of sepsis directly from venous blood and deliver an antibiotic susceptibility profile in ten hours. Both systems will report true minimal inhibitory concentration values.
Rapid AST directly from blood culture
ASTar™ is a fully automated instrument for Antibiotic Susceptibility Testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. ASTar shortens time to result, enabling early use of antibiotics specifically targeting the disease-causing pathogen.
Sepsis is a disease growing in prevalence – early discovery and diagnostics will be key to its management. By using a technology that eliminates the need for traditional blood cultures the ASTrID® platform will shorten the current lead times in sepsis treatment by several days. The ASTrID platform is currently under development with the goal to start CE-IVD validation in 2020 followed by FDA certification shortly after.